ID   M3K8_HUMAN              Reviewed;         467 AA.
AC   P41279; A8K2Q5; D3DRX1; Q14275; Q5T855; Q9HC81;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   12-OCT-2022, entry version 205.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 8;
DE            EC=2.7.11.25;
DE   AltName: Full=Cancer Osaka thyroid oncogene;
DE   AltName: Full=Proto-oncogene c-Cot;
DE   AltName: Full=Serine/threonine-protein kinase cot;
DE   AltName: Full=Tumor progression locus 2;
DE            Short=TPL-2;
GN   Name=MAP3K8; Synonyms=COT, ESTF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ONCOGENIC VARIANT.
RC   TISSUE=Hepatoma;
RX   PubMed=2072910; DOI=10.1128/mcb.11.8.4088-4096.1991;
RA   Miyoshi J., Higashi T., Mukai H., Ohuchi T., Kakunaga T.;
RT   "Structure and transforming potential of the human cot oncogene encoding a
RT   putative protein kinase.";
RL   Mol. Cell. Biol. 11:4088-4096(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=8226782; DOI=10.1016/s0021-9258(18)41587-6;
RA   Aoki M., Sugimoto T., Sumida S., Hamada F., Akiyama T., Toyoshima K.;
RT   "The human cot proto-oncogene encodes two protein serine/threonine kinases
RT   with different transforming activities by alternative initiation of
RT   translation.";
RL   J. Biol. Chem. 268:22723-22732(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Bone;
RX   PubMed=8479752;
RA   Chan A.M., Chedid M., McGovern E.S., Popescu N.C., Miki T., Aaronson S.A.;
RT   "Expression cDNA cloning of a serine kinase transforming gene.";
RL   Oncogene 8:1329-1333(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112.
RC   TISSUE=T-cell;
RX   PubMed=10896655; DOI=10.1074/jbc.m000382200;
RA   Sanchez-Gongora E., Lisbona C., de Gregorio R., Ballester A., Calvo V.,
RA   Perez-Jurado L., Alemany S.;
RT   "COT kinase proto-oncogene expression in T cells: implication of the
RT   JNK/SAPK signal transduction pathway in COT promoter activation.";
RL   J. Biol. Chem. 275:31379-31386(2000).
RN   [10]
RP   ALTERNATIVE INITIATION, FUNCTION, SUBCELLULAR LOCATION, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1833717;
RA   Aoki M., Akiyama T., Miyoshi J., Toyoshima K.;
RT   "Identification and characterization of protein products of the cot
RT   oncogene with serine kinase activity.";
RL   Oncogene 6:1515-1519(1991).
RN   [11]
RP   INTERACTION WITH NFKB1.
RX   PubMed=9950430; DOI=10.1038/16946;
RA   Belich M.P., Salmeron A., Johnston L.H., Ley S.C.;
RT   "TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein
RT   NF-kappaB1 p105.";
RL   Nature 397:363-368(1999).
RN   [12]
RP   FUNCTION.
RX   PubMed=11342626; DOI=10.4049/jimmunol.166.10.6084;
RA   Velasco-Sampayo A., Alemany S.;
RT   "p27kip protein levels and E2F activity are targets of Cot kinase during G1
RT   phase progression in T cells.";
RL   J. Immunol. 166:6084-6090(2001).
RN   [13]
RP   INTERACTION WITH KSR2.
RX   PubMed=12975377; DOI=10.1074/jbc.m306002200;
RA   Channavajhala P.L., Wu L., Cuozzo J.W., Hall J.P., Liu W., Lin L.-L.,
RA   Zhang Y.;
RT   "Identification of a novel human kinase supporter of Ras (hKSR-2) that
RT   functions as a negative regulator of Cot (Tpl2) signaling.";
RL   J. Biol. Chem. 278:47089-47097(2003).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH NFKB1.
RX   PubMed=12667451; DOI=10.1016/s1097-2765(03)00070-4;
RA   Waterfield M.R., Zhang M., Norman L.P., Sun S.C.;
RT   "NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase
RT   signaling by governing the stability and function of the Tpl2 kinase.";
RL   Mol. Cell 11:685-694(2003).
RN   [15]
RP   PHOSPHORYLATION AT THR-290, INTERACTION WITH KSR2, AND MUTAGENESIS OF
RP   THR-290.
RX   PubMed=15466476; DOI=10.1074/jbc.m403716200;
RA   Luciano B.S., Hsu S., Channavajhala P.L., Lin L.L., Cuozzo J.W.;
RT   "Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is
RT   necessary but not sufficient for kinase activity.";
RL   J. Biol. Chem. 279:52117-52123(2004).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH NFKB1 AND TNIP2.
RX   PubMed=15169888; DOI=10.1128/mcb.24.12.5235-5248.2004;
RA   Lang V., Symons A., Watton S.J., Janzen J., Soneji Y., Beinke S.,
RA   Howell S., Ley S.C.;
RT   "ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is
RT   essential for TPL-2 protein stability.";
RL   Mol. Cell. Biol. 24:5235-5248(2004).
RN   [17]
RP   PHOSPHORYLATION AT THR-290.
RX   PubMed=15699325; DOI=10.1073/pnas.0409856102;
RA   Cho J., Tsichlis P.N.;
RT   "Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and
RT   Tpl2 activation and degradation by lipopolysaccharide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:2350-2355(2005).
RN   [18]
RP   FUNCTION.
RX   PubMed=16371247; DOI=10.1016/j.cellsig.2005.10.016;
RA   Rodriguez C., Pozo M., Nieto E., Fernandez M., Alemany S.;
RT   "TRAF6 and Src kinase activity regulates Cot activation by IL-1.";
RL   Cell. Signal. 18:1376-1385(2006).
RN   [19]
RP   PHOSPHORYLATION AT THR-80; SER-400 AND SER-443.
RX   PubMed=17472361; DOI=10.1021/pr0700293;
RA   Black T.M., Andrews C.L., Kilili G., Ivan M., Tsichlis P.N., Vouros P.;
RT   "Characterization of phosphorylation sites on Tpl2 using IMAC enrichment
RT   and a linear ion trap mass spectrometer.";
RL   J. Proteome Res. 6:2269-2276(2007).
RN   [20]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=19001140; DOI=10.1084/jem.20081461;
RA   Watford W.T., Hissong B.D., Durant L.R., Yamane H., Muul L.M., Kanno Y.,
RA   Tato C.M., Ramos H.L., Berger A.E., Mielke L., Pesu M., Solomon B.,
RA   Frucht D.M., Paul W.E., Sher A., Jankovic D., Tsichlis P.N., O'Shea J.J.;
RT   "Tpl2 kinase regulates T cell interferon-gamma production and host
RT   resistance to Toxoplasma gondii.";
RL   J. Exp. Med. 205:2803-2812(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   RETRACTED PAPER.
RX   PubMed=19754427; DOI=10.1042/bj20091271;
RA   Handoyo H., Stafford M.J., McManus E., Baltzis D., Peggie M., Cohen P.;
RT   "IRAK1-independent pathways required for the interleukin-1-stimulated
RT   activation of the Tpl2 catalytic subunit and its dissociation from ABIN2.";
RL   Biochem. J. 424:109-118(2009).
RN   [23]
RP   RETRACTION NOTICE OF PUBMED:19754427.
RX   PubMed=24325551; DOI=10.1042/bj4570227;
RA   Stafford M.J., McManus E., Baltzis D., Peggie M., Cohen P.;
RT   "Retraction. IRAK1-independent pathways required for the interleukin-1-
RT   stimulated activation of the Tpl2 catalytic subunit and its dissociation
RT   from ABIN2.";
RL   Biochem. J. 457:227-227(2014).
RN   [24]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=19808894; DOI=10.2337/db09-0470;
RA   Jager J., Gremeaux T., Gonzalez T., Bonnafous S., Debard C., Laville M.,
RA   Vidal H., Tran A., Gual P., Le Marchand-Brustel Y., Cormont M., Tanti J.F.;
RT   "Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate
RT   interleukin-1beta and tumor necrosis factor-{alpha} effects on
RT   extracellular signal-regulated kinase activation and lipolysis.";
RL   Diabetes 59:61-70(2010).
RN   [25]
RP   PHOSPHORYLATION AT SER-400.
RX   PubMed=22988300; DOI=10.1128/mcb.01065-12;
RA   Roget K., Ben-Addi A., Mambole-Dema A., Gantke T., Yang H.T., Janzen J.,
RA   Morrice N., Abbott D., Ley S.C.;
RT   "IkappaB kinase 2 regulates TPL-2 activation of extracellular signal-
RT   regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400.";
RL   Mol. Cell. Biol. 32:4684-4690(2012).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-141, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Required for lipopolysaccharide (LPS)-induced, TLR4-mediated
CC       activation of the MAPK/ERK pathway in macrophages, thus being critical
CC       for production of the pro-inflammatory cytokine TNF-alpha (TNF) during
CC       immune responses. Involved in the regulation of T-helper cell
CC       differentiation and IFNG expression in T-cells. Involved in mediating
CC       host resistance to bacterial infection through negative regulation of
CC       type I interferon (IFN) production. In vitro, activates MAPK/ERK
CC       pathway in response to IL1 in an IRAK1-independent manner, leading to
CC       up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals
CC       that activate ERK in B-cells and macrophages, and thus may play a role
CC       in the regulation of immunoglobulin production. May also play a role in
CC       the transduction of TNF signals that activate JNK and NF-kappa-B in
CC       some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-
CC       dependent manner in response to IL1B and TNF, but not insulin, leading
CC       to induction of lipolysis. Plays a role in the cell cycle. Isoform 1
CC       shows some transforming activity, although it is much weaker than that
CC       of the activated oncogenic variant. {ECO:0000269|PubMed:11342626,
CC       ECO:0000269|PubMed:12667451, ECO:0000269|PubMed:15169888,
CC       ECO:0000269|PubMed:16371247, ECO:0000269|PubMed:1833717,
CC       ECO:0000269|PubMed:19001140, ECO:0000269|PubMed:19808894}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Forms a ternary complex with NFKB1/p105 and TNIP2. Interacts
CC       with NFKB1; the interaction increases the stability of MAP3K8 but
CC       inhibits its MEK phosphorylation activity, whereas loss of interaction
CC       following LPS stimulation leads to its degradation. Interacts with CD40
CC       and TRAF6; the interaction is required for ERK activation. Interacts
CC       with KSR2; the interaction inhibits ERK and NF-kappa-B activation.
CC       {ECO:0000269|PubMed:12667451, ECO:0000269|PubMed:12975377,
CC       ECO:0000269|PubMed:15169888, ECO:0000269|PubMed:15466476,
CC       ECO:0000269|PubMed:9950430}.
CC   -!- INTERACTION:
CC       P41279; P08238: HSP90AB1; NbExp=2; IntAct=EBI-354900, EBI-352572;
CC       P41279; P19838: NFKB1; NbExp=14; IntAct=EBI-354900, EBI-300010;
CC       P41279; Q00653: NFKB2; NbExp=2; IntAct=EBI-354900, EBI-307326;
CC       P41279; Q13526: PIN1; NbExp=8; IntAct=EBI-354900, EBI-714158;
CC       P41279; Q8NFZ5: TNIP2; NbExp=10; IntAct=EBI-354900, EBI-359372;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:1833717,
CC       ECO:0000269|PubMed:8226782}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=58 kDa;
CC         IsoId=P41279-1; Sequence=Displayed;
CC       Name=2; Synonyms=52 kDa;
CC         IsoId=P41279-2; Sequence=VSP_018843;
CC   -!- TISSUE SPECIFICITY: Expressed in several normal tissues and human
CC       tumor-derived cell lines.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is activated specifically during the S
CC       and G2/M phases of the cell cycle.
CC   -!- INDUCTION: Up-regulated by IL12 in T-lymphocytes. Up-regulated in
CC       subcutaneous adipose tissue of obese individuals.
CC       {ECO:0000269|PubMed:19001140, ECO:0000269|PubMed:19808894}.
CC   -!- PTM: Autophosphorylated (PubMed:8226782, PubMed:1833717). Isoform 1
CC       undergoes phosphorylation mainly on Ser residues, and isoform 2 on both
CC       Ser and Thr residues (PubMed:8226782). Phosphorylated on Thr-290; the
CC       phosphorylation is necessary but not sufficient for full kinase
CC       activity in vitro and for the dissociation of isoform 1 from NFKB1,
CC       leading to its degradation (PubMed:15466476, PubMed:15699325).
CC       Phosphorylated on Ser-400 by IKBKB; the phosphorylation is required for
CC       LPS-stimulated activation of the MAPK/ERK pathway in macrophages
CC       (PubMed:17472361, PubMed:22988300). {ECO:0000269|PubMed:15466476,
CC       ECO:0000269|PubMed:15699325, ECO:0000269|PubMed:17472361,
CC       ECO:0000269|PubMed:1833717, ECO:0000269|PubMed:22988300,
CC       ECO:0000269|PubMed:8226782}.
CC   -!- MISCELLANEOUS: Can be converted to an oncogenic protein by proviral
CC       activation, leading to a C-terminally truncated protein with
CC       transforming activity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: A paper describing a role for this protein in IRAK1-
CC       independent activation of the MAPK/ERK pathway in response to IL1 has
CC       been retracted, because some of the experimental data could not be
CC       reproduced. {ECO:0000305|PubMed:19754427, ECO:0000305|PubMed:24325551}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/map3k8/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D14497; BAA03387.1; -; mRNA.
DR   EMBL; Z14138; CAA78512.1; -; mRNA.
DR   EMBL; AK290320; BAF83009.1; -; mRNA.
DR   EMBL; AY309013; AAP45053.1; -; Genomic_DNA.
DR   EMBL; AL161651; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86004.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86005.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86006.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86007.1; -; Genomic_DNA.
DR   EMBL; BC104833; AAI04834.1; -; mRNA.
DR   EMBL; BC113566; AAI13567.1; -; mRNA.
DR   EMBL; AF133211; AAG13454.1; -; Genomic_DNA.
DR   CCDS; CCDS7166.1; -. [P41279-1]
DR   PIR; A48713; A48713.
DR   RefSeq; NP_001231063.1; NM_001244134.1. [P41279-1]
DR   RefSeq; NP_001307890.1; NM_001320961.1. [P41279-1]
DR   RefSeq; NP_005195.2; NM_005204.3. [P41279-1]
DR   RefSeq; XP_016871196.1; XM_017015707.1.
DR   RefSeq; XP_016871197.1; XM_017015708.1. [P41279-1]
DR   RefSeq; XP_016871198.1; XM_017015709.1. [P41279-1]
DR   RefSeq; XP_016871199.1; XM_017015710.1. [P41279-1]
DR   PDB; 4Y83; X-ray; 2.89 A; A/B/C=66-395.
DR   PDB; 4Y85; X-ray; 2.33 A; A/B/C=66-395.
DR   PDB; 5IU2; X-ray; 2.70 A; A/B=66-395.
DR   PDBsum; 4Y83; -.
DR   PDBsum; 4Y85; -.
DR   PDBsum; 5IU2; -.
DR   AlphaFoldDB; P41279; -.
DR   SMR; P41279; -.
DR   BioGRID; 107719; 27.
DR   CORUM; P41279; -.
DR   DIP; DIP-27534N; -.
DR   IntAct; P41279; 14.
DR   MINT; P41279; -.
DR   STRING; 9606.ENSP00000263056; -.
DR   BindingDB; P41279; -.
DR   ChEMBL; CHEMBL4899; -.
DR   GuidetoPHARMACOLOGY; 2083; -.
DR   iPTMnet; P41279; -.
DR   PhosphoSitePlus; P41279; -.
DR   BioMuta; MAP3K8; -.
DR   DMDM; 50403742; -.
DR   CPTAC; CPTAC-858; -.
DR   CPTAC; CPTAC-859; -.
DR   EPD; P41279; -.
DR   jPOST; P41279; -.
DR   MassIVE; P41279; -.
DR   MaxQB; P41279; -.
DR   PaxDb; P41279; -.
DR   PeptideAtlas; P41279; -.
DR   PRIDE; P41279; -.
DR   ProteomicsDB; 55458; -. [P41279-1]
DR   ProteomicsDB; 55459; -. [P41279-2]
DR   Antibodypedia; 2836; 620 antibodies from 36 providers.
DR   DNASU; 1326; -.
DR   Ensembl; ENST00000263056.6; ENSP00000263056.1; ENSG00000107968.10. [P41279-1]
DR   Ensembl; ENST00000375321.1; ENSP00000364470.1; ENSG00000107968.10. [P41279-1]
DR   Ensembl; ENST00000542547.5; ENSP00000443610.1; ENSG00000107968.10. [P41279-1]
DR   GeneID; 1326; -.
DR   KEGG; hsa:1326; -.
DR   MANE-Select; ENST00000263056.6; ENSP00000263056.1; NM_005204.4; NP_005195.2.
DR   UCSC; uc001ivi.3; human. [P41279-1]
DR   CTD; 1326; -.
DR   DisGeNET; 1326; -.
DR   GeneCards; MAP3K8; -.
DR   HGNC; HGNC:6860; MAP3K8.
DR   HPA; ENSG00000107968; Tissue enriched (bone).
DR   MalaCards; MAP3K8; -.
DR   MIM; 191195; gene.
DR   neXtProt; NX_P41279; -.
DR   OpenTargets; ENSG00000107968; -.
DR   PharmGKB; PA30606; -.
DR   VEuPathDB; HostDB:ENSG00000107968; -.
DR   eggNOG; KOG0201; Eukaryota.
DR   GeneTree; ENSGT00940000158806; -.
DR   HOGENOM; CLU_047137_0_0_1; -.
DR   InParanoid; P41279; -.
DR   OMA; FPWRLTY; -.
DR   PhylomeDB; P41279; -.
DR   TreeFam; TF105117; -.
DR   PathwayCommons; P41279; -.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SignaLink; P41279; -.
DR   SIGNOR; P41279; -.
DR   BioGRID-ORCS; 1326; 14 hits in 1116 CRISPR screens.
DR   ChiTaRS; MAP3K8; human.
DR   GeneWiki; MAP3K8; -.
DR   GenomeRNAi; 1326; -.
DR   Pharos; P41279; Tchem.
DR   PRO; PR:P41279; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P41279; protein.
DR   Bgee; ENSG00000107968; Expressed in mucosa of stomach and 159 other tissues.
DR   ExpressionAtlas; P41279; baseline and differential.
DR   Genevisible; P41279; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017424; MAPKKK8.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF038171; MAPKKK8; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; ATP-binding; Cell cycle; Cytoplasm;
KW   Immunity; Kinase; Magnesium; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..467
FT                   /note="Mitogen-activated protein kinase kinase kinase 8"
FT                   /id="PRO_0000024350"
FT   DOMAIN          138..388
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        253
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         144..152
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         167
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         80
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17472361"
FT   MOD_RES         141
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         290
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15466476,
FT                   ECO:0000269|PubMed:15699325"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17472361,
FT                   ECO:0000269|PubMed:22988300"
FT   MOD_RES         443
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17472361"
FT   VAR_SEQ         1..29
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8226782"
FT                   /id="VSP_018843"
FT   VARIANT         214
FT                   /note="S -> F (in dbSNP:rs3087944)"
FT                   /id="VAR_051638"
FT   VARIANT         398..415
FT                   /note="CQSLDSALLERKRLLSRK -> GHQVIHEGSSTNDPNNSC (in
FT                   oncogenic form)"
FT                   /id="VAR_006198"
FT   VARIANT         416..467
FT                   /note="Missing (in oncogenic form)"
FT                   /id="VAR_006199"
FT   MUTAGEN         290
FT                   /note="T->A: Loss of MEK phosphorylation activity and
FT                   almost abolished autophosphorylation activity. Loss of
FT                   IL1-stimulated MEK phosphorylation activity but not of
FT                   IL1-stimulated autophosphorylation activity. No effect on
FT                   KSR2 binding."
FT                   /evidence="ECO:0000269|PubMed:15466476"
FT   MUTAGEN         290
FT                   /note="T->D: Impaired MEK phosphorylation and
FT                   autophosphorylation activities. No effect on KSR2 binding."
FT                   /evidence="ECO:0000269|PubMed:15466476"
FT   MUTAGEN         290
FT                   /note="T->E: Loss of MEK phosphorylation activity and
FT                   almost abolished autophosphorylation activity. No effect on
FT                   KSR2 binding."
FT                   /evidence="ECO:0000269|PubMed:15466476"
FT   CONFLICT        399
FT                   /note="Q -> T (in Ref. 1; BAA03387 and 2; no nucleotide
FT                   entry)"
FT                   /evidence="ECO:0000305"
FT   STRAND          75..78
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           81..92
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          106..109
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          117..119
FT                   /evidence="ECO:0007829|PDB:4Y83"
FT   TURN            124..126
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          127..130
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           135..137
FT                   /evidence="ECO:0007829|PDB:4Y83"
FT   STRAND          138..145
FT                   /evidence="ECO:0007829|PDB:4Y83"
FT   STRAND          148..157
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   TURN            158..160
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          163..170
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           171..173
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           177..184
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          193..199
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          202..207
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           215..222
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           227..246
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          259..261
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          278..282
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           291..293
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           296..300
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           307..322
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   TURN            326..330
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           340..346
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   STRAND          355..357
FT                   /evidence="ECO:0007829|PDB:5IU2"
FT   HELIX           359..368
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   TURN            373..375
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           379..382
FT                   /evidence="ECO:0007829|PDB:4Y85"
FT   HELIX           386..388
FT                   /evidence="ECO:0007829|PDB:4Y85"
SQ   SEQUENCE   467 AA;  52925 MW;  7728969EA3E4E8EC CRC64;
     MEYMSTGSDN KEEIDLLIKH LNVSDVIDIM ENLYASEEPA VYEPSLMTMC QDSNQNDERS
     KSLLLSGQEV PWLSSVRYGT VEDLLAFANH ISNTAKHFYG QRPQESGILL NMVITPQNGR
     YQIDSDVLLI PWKLTYRNIG SDFIPRGAFG KVYLAQDIKT KKRMACKLIP VDQFKPSDVE
     IQACFRHENI AELYGAVLWG ETVHLFMEAG EGGSVLEKLE SCGPMREFEI IWVTKHVLKG
     LDFLHSKKVI HHDIKPSNIV FMSTKAVLVD FGLSVQMTED VYFPKDLRGT EIYMSPEVIL
     CRGHSTKADI YSLGATLIHM QTGTPPWVKR YPRSAYPSYL YIIHKQAPPL EDIADDCSPG
     MRELIEASLE RNPNHRPRAA DLLKHEALNP PREDQPRCQS LDSALLERKR LLSRKELELP
     ENIADSSCTG STEESEMLKR QRSLYIDLGA LAGYFNLVRG PPTLEYG
//
